Vencor, Inc. 10-Q Summary: Period Ended June 30, 1995
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Vencor, Inc., a healthcare company operating hospitals and ancillary services, for the period ended June 30, 1995. The company operates 36 hospitals as of the reporting date, up from 31 in the prior year. The financial statements are unaudited. Note: The input metadata referenced "Ventas, Inc.", but the filing text explicitly identifies the registrant as "Vencor, Inc."
Key Financial Metrics
| Metric | Six Months Ended June 30, 1995 | Six Months Ended June 30, 1994 |
|---|---|---|
| Total Net Revenues | $261,094,000 | $185,497,000 |
| Net Income | $19,961,000 | $13,202,000 |
| Diluted EPS | $0.66 | $0.49 |
| Operating Cash Flow | $21,584,000 | $6,340,000 |
| Total Assets | $495,788,000 | $390,372,000 |
| Total Long-Term Debt | $144,285,000 | $141,899,000 |
| Working Capital | $95,591,000 | $74,133,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 40.8% year-over-year, driven by a 41.0% increase in net patient revenues. Growth was attributed to higher patient census, increased payment rates, expansion of the "Vencare" program (respiratory and subacute care), and the addition of new hospitals.
- Profitability: Net income rose 51.2% to $19.96 million. Operating expenses increased 39.7%, largely due to costs associated with new facilities and the Vencare program.
- Acquisitions: The company acquired five hospitals and ancillary entities for a net cost of approximately $29 million in the first six months of 1995.
- Capital Structure: In February 1995, the company sold 2.2 million shares of common stock, raising net proceeds of $66.5 million. Approximately $33 million of these proceeds were used to reduce debt under the revolving credit agreement.
- Debt Capacity: The revolving credit agreement was amended in January 1995 to increase availability from $100 million to $200 million.
Guidance, Outlook, and Risks
- Proposed Merger: On April 23, 1995, Vencor entered a definitive agreement to merge with Hillhaven Corporation in a tax-free stock-for-stock transaction. The deal is subject to regulatory and shareholder approval.
- Merger Costs: The company anticipates pre-tax merger expenses of approximately $50 million. Additionally, refinancing Hillhaven's debt is expected to result in after-tax losses of approximately $18 million, reducing the combined entity's net income.
- Future Financing: Upon consummation of the merger, the company expects to enter a $1 billion senior credit facility to replace existing credit agreements and refinance Hillhaven's debt (approx. $660 million).
- Expansion Plans: Management intends to purchase or lease 10 to 12 additional hospitals over the next two to three years and secure at least 200 additional respiratory/subacute care contracts annually.
- Risks: The filing notes professional liability risks regarding medical malpractice, though management believes current reserves and insurance are adequate.
Investor Verification Checklist
- Verify the status of the proposed merger with Hillhaven Corporation and the likelihood of regulatory approval.
- Confirm the impact of the anticipated $18 million after-tax loss from debt refinancing on future earnings projections.
- Review the sustainability of the 40%+ revenue growth rate, specifically the contribution from the Vencare program versus organic hospital growth.
- Monitor the company's ability to service the proposed $1 billion credit facility post-merger.
- Assess the adequacy of the $2.9 million allowance for doubtful accounts given the 38.7% increase in net patient accounts receivable.